The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
142
NNC0721-8060 will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Placebo will be administered subcutaneously.
ICON Early Phase Services, LLC
Lenexa, Kansas, United States
RECRUITINGICON
San Antonio, Texas, United States
NOT_YET_RECRUITINGPart A: Number of treatment emergent adverse events (TEAE)
Measured as number of events.
Time frame: From Day 1 to Day 36
Part B: Number of treatment emergent adverse events (TEAE)
Measured as number of events.
Time frame: From Day 1 to Day 57
Part C: Change from baseline in body weight
Measured as percentage change in body weight.
Time frame: From Day 1 to Day 85
Part A: AUC- Area under the NNC0721-8060 plasma concentration time-curve
Measured as hour nanomoles per litre (h\*nmol/L).
Time frame: From Day 1 to Day 36
Part A: Cmax- Maximum observed plasma concentration of NNC0721-8060
Measured as nanomoles per litre (nmol/L).
Time frame: From Day 1 to Day 36
Part B: AUC- Area under the NNC0721-8060 plasma concentration time-curve
Measured as h\*nmol/L.
Time frame: From Day 1 to Day 57
Part B: Cmax- Maximum observed plasma concentration of NNC0721-8060
Measured as nmol/L.
Time frame: From Day 1 to Day 57
Part C: AUC- Area under the NNC0721-8060 plasma concentration time-curve
Measured as h\*nmol/L.
Time frame: From Day 1 to Day 113
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Part C: Cmax- Maximum observed plasma concentration of NNC0721-8060
Measured as nmol/L.
Time frame: From Day 1 to Day 113
Part C: Number of treatment emergent adverse events (TEAE)
Measured as number of events.
Time frame: From Day 1 to Day 113